Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
Zovegalisib (RLY-2608) is the first pan-mutant-selective PI3Kα inhibitor, binding a novel allosteric site distinct from ...
Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results